ATE329926T1 - Verfahren und zusammensetzungen für die behandlung von neoplastichen krankheiten - Google Patents

Verfahren und zusammensetzungen für die behandlung von neoplastichen krankheiten

Info

Publication number
ATE329926T1
ATE329926T1 AT97942549T AT97942549T ATE329926T1 AT E329926 T1 ATE329926 T1 AT E329926T1 AT 97942549 T AT97942549 T AT 97942549T AT 97942549 T AT97942549 T AT 97942549T AT E329926 T1 ATE329926 T1 AT E329926T1
Authority
AT
Austria
Prior art keywords
fragments
plasminogen
provides
methods
plasminogen activator
Prior art date
Application number
AT97942549T
Other languages
German (de)
English (en)
Inventor
Gerald Soff
Stephen T Gately
Przemyslaw Twardowski
Original Assignee
Univ Northwestern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Northwestern filed Critical Univ Northwestern
Application granted granted Critical
Publication of ATE329926T1 publication Critical patent/ATE329926T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT97942549T 1996-09-17 1997-09-17 Verfahren und zusammensetzungen für die behandlung von neoplastichen krankheiten ATE329926T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/710,305 US5801012A (en) 1996-09-17 1996-09-17 Methods and compositions for generating angiostatin

Publications (1)

Publication Number Publication Date
ATE329926T1 true ATE329926T1 (de) 2006-07-15

Family

ID=24853480

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97942549T ATE329926T1 (de) 1996-09-17 1997-09-17 Verfahren und zusammensetzungen für die behandlung von neoplastichen krankheiten

Country Status (9)

Country Link
US (2) US5801012A (enExample)
EP (2) EP0964869B1 (enExample)
JP (1) JP4160121B2 (enExample)
AT (1) ATE329926T1 (enExample)
AU (1) AU4422797A (enExample)
CA (1) CA2265550A1 (enExample)
DE (1) DE69736129T2 (enExample)
ES (1) ES2267151T3 (enExample)
WO (1) WO1998015574A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945403A (en) * 1997-05-30 1999-08-31 The Children's Medical Center Corporation Angiostatin fragments and method of use
US7297331B2 (en) * 1996-04-03 2007-11-20 The Rogosin Institute Beads containing restricted cancer cells producing material suppressing cancer cell proliferation
EP1001985A1 (en) * 1997-06-26 2000-05-24 Karolinska Innovations AB Kringle domains 1-5 of plasminogen, capable of modulating angiogenesis in vivo
AU1731300A (en) * 1998-11-25 2000-06-13 Bristol-Myers Squibb Company Compositions comprising angiostatin and kringle 5 region of plasminogen and methods of use thereof
CA2384929C (en) 1999-09-15 2006-12-05 Mogam Biotechnology Research Institute A novel angiogenesis inhibitor
WO2001058921A2 (en) * 2000-02-08 2001-08-16 Northwestern University Methods and compositions for generating angiostatin
AU8591901A (en) 2000-09-05 2002-03-22 Karolinska Innovations Ab Materials and methods relating to endothelial cell growth inhibitors
DE60134885D1 (de) 2000-11-28 2008-08-28 David M Waisman Antiangiogene polypeptide
ITMI20011995A1 (it) * 2001-09-26 2003-03-26 Ist Naz Ricerca Sul Cancro Sostanze ad attivita' antinfiammatoria
US7285277B2 (en) * 2002-03-15 2007-10-23 Mogam Biotechnology Research Institute Anticancer agent
CA2491041A1 (en) * 2002-07-02 2004-01-15 Novartis Ag Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
CA2514873C (en) * 2002-12-13 2012-01-03 David Waisman Compositions and methods for inhibiting tumor growth and metastasis
US7090654B2 (en) * 2003-03-28 2006-08-15 Sherwood Services Ag Catheter with occlusion resistant tip
US7141035B2 (en) * 2003-03-28 2006-11-28 Sherwood Services Ag Catheter with occlusion resistant tip
US7776005B2 (en) * 2003-03-28 2010-08-17 Covidien Ag Triple lumen catheter with occlusion resistant tip
US20050281879A1 (en) * 2003-11-14 2005-12-22 Guohua Chen Excipients in drug delivery vehicles
CN1889929B (zh) * 2003-11-14 2013-04-10 阿尔萨公司 药物递送媒介物中的赋形剂
KR20070106979A (ko) * 2004-11-04 2007-11-06 코비디엔 아게 카테터 삽입 장치
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
WO2009100617A1 (zh) * 2008-02-04 2009-08-20 Shanghai First People's Hospital 抑制血管新生的多肽及其应用
US8187231B2 (en) * 2009-06-26 2012-05-29 Tyco Healthcare Group Lp Catheterization system
CA2715857A1 (en) 2009-09-30 2011-03-30 Tyco Healthcare Group Lp Medical catheter having a design providing low recirculation and reversibility
US9072867B2 (en) 2011-09-30 2015-07-07 Covidien Lp Catheter with external flow channel
US8747343B2 (en) 2011-09-30 2014-06-10 Covidien Lp Hemodialysis catheter with improved side opening design
US9216163B2 (en) 2013-05-20 2015-12-22 Kyorin Pharmaceutical Co., Ltd. Method of inhibiting angiogenesis
WO2021146215A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
CA3203561A1 (en) 2021-01-12 2022-07-21 Adrian Neil Verity Sustained release drug delivery systems and related methods

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2431342C3 (de) * 1973-07-27 1978-10-26 Behringwerke Ag, 3550 Marburg Verfahren zur Messung des Plasminogengehaltes durch Bestimmung der Bildung von Fibrin in einer Probe
US4968494A (en) * 1987-03-27 1990-11-06 Merck & Co., Inc. Methods and compositions for thrombolytic therapy
US5135919A (en) 1988-01-19 1992-08-04 Children's Medical Center Corporation Method and a pharmaceutical composition for the inhibition of angiogenesis
US5021404A (en) 1988-04-20 1991-06-04 The Children's Medical Center Corporation Angiostatic collagen modulators
EP0359036B1 (en) 1988-09-01 1997-03-26 Takeda Chemical Industries, Ltd. Fumagillol derivatives
PT93847A (pt) 1989-04-24 1990-11-20 Harvard College Processo para a preparacao de oligossacaridos de baixo peso molecular derivados de heparina ou de sulfato de heparano despolimerizados e de composicoes farmaceuticas que os contem
US5290807A (en) 1989-08-10 1994-03-01 Children's Medical Center Corporation Method for regressing angiogenesis using o-substituted fumagillol derivatives
US5192744A (en) 1990-01-12 1993-03-09 Northwestern University Method of inhibiting angiogenesis of tumors
US5504074A (en) 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US5639725A (en) * 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
US5945403A (en) 1997-05-30 1999-08-31 The Children's Medical Center Corporation Angiostatin fragments and method of use
US5837682A (en) 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
CN1636594B (zh) * 1994-04-26 2012-08-29 儿童医学中心公司 血管生成抑制素和用于抑制血管生成的方法
MX9708217A (es) 1995-04-26 1997-12-31 Childrens Medical Center Fragmentos de angiostatina y angiostatina agregada y metodos de uso.
US5861372A (en) 1996-02-22 1999-01-19 The Children's Medical Center Corporation Aggregate angiostatin and method of use
AU6264596A (en) 1995-06-07 1996-12-30 Children's Medical Center Corporation Diagnosis, prognosis and monitoring of angiogenesis dependen t diseases
DE19529223A1 (de) * 1995-08-09 1997-02-13 Boehringer Mannheim Gmbh Verwendung von Plasminogenaktivatoren zum lokalen Knochenaufbau
EP0857210B1 (en) 1995-10-23 2003-09-03 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
US5854221A (en) 1996-12-12 1998-12-29 The Children's Medical Center Corporation Endothelial cell proliferation inhibitor and method of use
ES2217340T3 (es) 1995-12-13 2004-11-01 The Children's Medical Center Corporation Inhibidor de la proliferacion de celulas endoteliales y utilizacion de este.
JP4426650B2 (ja) 1996-05-03 2010-03-03 アボット・ラボラトリーズ 新規な抗血管形成ペプチド、それをコードするポリヌクレオチド、および血管形成を阻害する方法
EP1001985A1 (en) 1997-06-26 2000-05-24 Karolinska Innovations AB Kringle domains 1-5 of plasminogen, capable of modulating angiogenesis in vivo

Also Published As

Publication number Publication date
EP0964869B1 (en) 2006-06-14
EP0964869A4 (en) 2003-06-04
WO1998015574A1 (en) 1998-04-16
JP2001502534A (ja) 2001-02-27
CA2265550A1 (en) 1998-04-16
DE69736129D1 (de) 2006-07-27
ES2267151T3 (es) 2007-03-01
JP4160121B2 (ja) 2008-10-01
EP0964869A1 (en) 1999-12-22
US6576609B1 (en) 2003-06-10
EP1705184A1 (en) 2006-09-27
US5801012A (en) 1998-09-01
DE69736129T2 (de) 2007-01-04
AU4422797A (en) 1998-05-05

Similar Documents

Publication Publication Date Title
DE69736129D1 (de) Verfahren und Zusammensetzungen für die Behandlung von neoplastichen Krankheiten
ATE459369T1 (de) Verfahren zur behandlung von entzündungen
DE69535375D1 (de) Lösliche polypeptidfraktionen des lag-3-proteins; verfahren zur herstellung; therapeutische zusamensetzung; antiidiotypischer antikörper
ES2181674T3 (es) Dominios de union en las proteinas notch y delta.
ATE198712T1 (de) Verfahren und zusammensetzungen für die spezifische koagulation von tumorgefässen
DK0662827T4 (da) Terapeutiske og diagnostiske fremgangsmåder og sammensætninger baseret på Notch-proteiner og nucleinsyrer
NO995044D0 (no) Osteoprotegerinbindende proteiner og reseptorer
DE69921102D1 (de) Verfahren zur verbesserung der serum halbwertszeit von biologisch aktiven molekülen
PT87138A (pt) Process for the preparation of adn recombinant molecules codin g polypeptide adn segments and of antibody compositions relate d with human tissue factor
NZ236511A (en) Polypeptides containing sequences from residues 61 to 82 or 104 to 129 of human il-4 or subsequences thereof; antibodies and pharmaceutical compositions
DE69836139D1 (de) Verfahren zur behandlung von vaskulären proliferativen erkrankungen mit p27 und fusionen davon
ATE277081T1 (de) Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten
DK384084A (da) Vaeksthormonfrigoerende peptider samt fremgangsmaade til behandling af pattedyr hermed
DK0953576T3 (da) Aktivt hedgehog-proteinkonjugat, fremgangsmåde til fremstilling heraf og anvendelse
ATE360695T1 (de) Cortistatin: neuropeptide, zusammensetzungen und methoden
ATE377026T1 (de) Behandlung von fettleibigkeit
ES2113878T3 (es) Proteina c hibrida.
Camacho et al. Limited proteolysis of tumor cells increases their plasmin-binding ability
ATE292471T1 (de) Peptide des tsp-i-rezeptors cd36 zur behandlung von krankheiten welche durch eine fehlregulation von tgf-beta1 verursacht werden
KR900702017A (ko) 혼성 단백질(bybrid proteins)
DE3883315D1 (de) Neue fibrinolytische enzyme.
DE3751218D1 (de) Verfahren und therapeutische Zubereitungen für die Behandlung von Gerinnungsstörungen.
Makogonenko et al. Factor XIIIa incorporates thymosin β4 preferentially into the fibrin (ogen) αC-domains
PT639225E (pt) Polipeptidos e peptidos novos acidos nucleicos que codificam para aqueles e sua utilizacao na area da terapia tumoral inflamacao ou imunologia
WO2001058921A3 (en) Methods and compositions for generating angiostatin

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0964869

Country of ref document: EP

REN Ceased due to non-payment of the annual fee